New trial
Phase 1b trial: Tazemetostat EZH2 inhibitor with Zanubrutinib BTK inhibitor in indolent NHL.
- Trial ID
- NCT06824701 on ClinicalTrials.gov
- Cancer type
- Non-Hodgkin Lymphoma
- Stage of research
- Exploratory
- Published in
- New in Oncology - July 11, 2025
This trial led by University of Utah evaluates the safety and preliminary efficacy of Tazemetostat (an EZH2 inhibitor) in combination with Zanubrutinib (a BTK inhibitor) and anti-CD20 monoclonal antibodies (rituximab or obinutuzumab) in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, including various subtypes. The study uses a single-group design to assess combination safety and potential clinical activity.
More in lymphoma
-
Trial result · Oct 22, 2026 · NCT04245839
Liso-cel (CD19 CAR-T) Delivers 100% CR/ORR With Minimal CRS/Neurotoxicity in Japanese R/R FL -
Trial result · Oct 22, 2026 · NCT05800366
Glofitamab (CD3×CD20) + pola-R-CHP (CD79b ADC + anti-CD20 chemoimmunotherapy) drives 95% CR and 95% 24‑mo PFS in high-risk 1L DLBCL -
Trial result · Oct 15, 2026 · NCT03618550
Pembrolizumab-GVD followed by autologous transplantation shows 91% five-year PFS in relapsed/refractory classical Hodgkin lymphoma -
Trial result · Oct 15, 2026 · NCT03598608
Favezelimab (anti–LAG-3) + pembrolizumab (PD-1) reports 83% ORR in PD-1–naive R/R cHL; development discontinued -
Trial result · Oct 1, 2026
Mosunetuzumab (CD20xCD3 bispecific) + response-adapted polatuzumab vedotin (CD79b ADC) drives 86% PET-CR and 89% 2y PFS in untreated indolent NHL